Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma

201576 citationsJournal Articlebronze Open Access

Authors

Collectively, these data strongly suggest that the combination of pralatrexate and romidepsin merits clinical study in patients with TCLs.

Good health and well-being

Published in: Clinical Cancer Research

Volume 21, Issue 9, pp. 2096-2106

Field-Weighted Citation Impact: 2.46